Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Wang, Xiaoli; Wu, Jingjing; Zhang, Mingzhi

doi:10.1080/16078454.2019.1613290

Cited by 5 publications

(4 citation statements)

References 46 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the first-line treatment for patients diagnosed with systemic ALCL is represented by CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) standard chemotherapy, but the recurrence of refractory or relapsed disease entailed the use of stem cell transplantation and the FDA approval of four novel single-agent treatments: pralatrexate, a folic acid antagonist, romidepsin and belinostat, two histone deacetylase inhibitors and Brentuximab vedotin, a drug-conjugated monoclonal antibody directed to CD30-expressing cells [37]. Over the last decades, the immunotherapeutic approach has gained an ever-growing interest in the treatment of several hematological malignancies [28,38] because the presence of circulating cancer cells and the expression of a rich repertoire of surface antigens make these kinds of diseases good candidates for monoclonal antibody (mAb)-based therapies.…”

Section: Discussionmentioning

confidence: 99%

Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma

Belmonte

Cancila

Gulino

et al. 2021

Cancers

View full text Add to dashboard Cite

Due to the high expression of P-selectin glycoprotein ligand-1 (PSGL-1) in lymphoproliferative disorders and in multiple myeloma, it has been considered as a potential target for humoral immunotherapy, as well as an immune checkpoint inhibitor in T-cells. By investigating the expression of SELPLG in 678 T- and B-cell samples by gene expression profiling (GEP), further supported by tissue microarray and immunohistochemical analysis, we identified anaplastic large T-cell lymphoma (ALCL) as constitutively expressing SELPLG at high levels. Moreover, GEP analysis in CD30+ ALCLs highlighted a positive correlation of SELPLG with TNFRSF8 (CD30-coding gene) and T-cell receptor (TCR)-signaling genes (LCK, LAT, SYK and JUN), suggesting that the common dysregulation of TCR expression in ALCLs may be bypassed by the involvement of PSGL-1 in T-cell activation and survival. Finally, we evaluated the effects elicited by in vitro treatment with two anti-PSGL-1 antibodies (KPL-1 and TB5) on the activation of the complement system and induction of apoptosis in human ALCL cell lines. In conclusion, our data demonstrated that PSGL-1 is specifically enriched in ALCLs, altering cell motility and viability due to its involvement in CD30 and TCR signaling, and it might be considered as a promising candidate for novel immunotherapeutic approaches in ALCLs.

show abstract

Section: Discussionmentioning

confidence: 99%

Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma

Belmonte

Cancila

Gulino

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…ALCL is a CD30+ positive T cell lymphoma with its own characteristic morphology and immunophenotype[14]. According to the expression of ALK, the WHO 2016 classification system divided ALCL into four entities: systemic ALK-positive ALCL (ALCL, ALK+), systemic ALK-negative ALCL (ALCL, ALK-), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL)[2].…”

Section: Discussionmentioning

confidence: 99%

Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma masquerading as Behcet's disease: A case report and review of literature

Luo

Jiang

Lei

et al. 2019

WJCC

View full text Add to dashboard Cite

BACKGROUNDAnaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma, a rare type of non-Hodgkin lymphoma. The current World Health Organization classification system divides ALCLs into anaplastic lymphoma kinase (ALK)-positive and ALK-negative groups. ALCL rarely presents in the gastrointestinal tract.CASE SUMMARYA 54-year-old male was admitted to the department of gastroenterology for abdominal pain. He presented with lower abdominal pain, diarrhea and recurrent oral and penile ulcers. He was misdiagnosed with Behcet's disease and treated with prednisone. But after one month, he was hospitalized in another hospital for reexamination. This time, the lesion on the penis was biopsied for histological examination. The final pathological diagnosis was ALCL, ALK-negative. The patient was treated with cyclophosphamide, doxorubicin, vincristine, prednisolone chemotherapy. However, he died within one month.CONCLUSIONGastrointestinal ALCL needs to be considered in the differential diagnosis to avoid delaying treatment. Repeated biopsy is the most important for early diagnosis and treatment.

show abstract

“…Anaplastic large cell lymphoma (ALCL), defined as a CD30 positive peripheral T-cell neoplasma, accounts for 6% to 24% T-cell lymphomas. [ 1 ] Multiple myeloma (MM) is a disease defined as the B cell neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. [ 2 ] Co-existence of lymphoproliferative neoplasms of B and T-cell lineage in the same patient is rare.…”

Section: Introductionmentioning

confidence: 99%

Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient

Shi

Jiang

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationale: Synchronous development of both anaplastic large cell lymphoma (ALCL) and multiple myeloma (MM) in a patient is rare. To our knowledge, until now only one case has been reported. Treatment needs to cover both and is a challenge. Here we reported another case and discussed the diagnosis and treatment. Patient concerns: This is a 63-year old woman who presented with a mass in upper abdominal skin. Positron emission tomography/computed tomography (PET/CT) showed the high metabolism in left abdominal skin and left axillary lymph nodes. Histopathologic and immunohistochemical evaluation identified the cutaneous mass as an ALK-negative ALCL. Bone marrow smear showed increased plasma cells which expressed CD38, CD138, and cLambda concomitantly. The increased monoclonal immunoglobulin IgD λ was detected by immunofixation electrophoresis. Diagnoses: Diagnosis of both ALCL and MM was confirmed. Interventions: The patient successively received 6 cycles of B-CHOD regimen, one cycle of ID regimen, 2 cycles of DHAX regimen, one cycle of L-DA-EPOCH and autologous stem cell transplantation (ASCT). Then lenalidomide was performed as a maintenance therapy. Outcomes: Both ALCL and MM achieved complete remission. Lessons: We reported a very rare case with synchronous development of ALCL and MM, in whom a good therapeutic response to chemotherapies followed by ASCT has been observed.

show abstract

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

Cited by 5 publications

References 46 publications

Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma

Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma

Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma masquerading as Behcet's disease: A case report and review of literature

Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient

Contact Info

Product

Resources

About